Training Network for Optimizing Adoptive T cell Therapy of Cancer

Project description

Optimisation of T cell therapy

Adoptive T cell therapy, which employs the patient's own cells as a weapon, is considered a breakthrough in the treatment of cancer. However, the production of such immunotherapy products lacks harmonisation with clinical studies. The EU-funded T-OP project aims to bridge this gap by bringing together interdisciplinary teams of scientists working in cell therapy, immunology, protein engineering and bioinformatics alongside large and medium-sized enterprises. The scientific work will focus on cytokines and their role in the therapeutic outcome of adoptive cell therapy, aiming to determine the optimal combination. The project's results will lead to the development of safer and improved immunotherapeutics.

Field of science

• /natural sciences/biological sciences/biochemistry/biomolecules/proteins
• /medical and health sciences/basic medicine/immunology
• /medical and health sciences/clinical medicine/cancer
• /medical and health sciences/medical biotechnology/cells technologies

Programme(s)

• H2020-EU.1.3.1. - Fostering new skills by means of excellent initial training of researchers

Topic(s)

• MSCA-ITN-2020 - Innovative Training Networks

Call for proposal

H2020-MSCA-ITN-2020
See other projects for this call

Funding Scheme

MSCA-ITN-ETN - European Training Networks

Coordinator

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

Address

Geschwister Scholl Platz 1
80539 Muenchen
Germany

Activity type

Higher or Secondary Education Establishments

EU contribution

€ 758 365,20

Participants (11)

DANMARKS TEKNISKE UNIVERSITET

Denmark

EU contribution

€ 297 522

Address

Anker Engelundsvej 1 Bygning 101 A
2800 Kgs Lyngby

Activity type

Higher or Secondary Education Establishments

STICHTING VUMC

Netherlands

EU contribution

€ 265 619,88

Address

De Boelelaan 1117
1081 HV Amsterdam

Activity type

Research Organisations

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU contribution

€ 274 802,04

Address

Rue De Tolbiac 101
75654 Paris

Activity type

Research Organisations

BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL

Germany

EU contribution

€ 252 788,40

Address

Paul-ehrlich-strasse 51-59
63225 Langen

Activity type

Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)

REGION HOVEDSTADEN

Denmark

EU contribution

€ 595 044

Address

Kongens Vaenge 2
3400 Hillerod

Activity type

Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)

UNIVERSITAT BASEL

Switzerland

EU contribution

€ 281 276,64

Address

Petersplatz 1
4051 Basel

Activity type

Higher or Secondary Education Establishments

ROCHE GLYCART AG

Switzerland

EU contribution

€ 281 276,64

Address

Wagistrasse 10
8952 Schlieren

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

IMMETACYTE LIMITED

United Kingdom

EU contribution

€ 303 172,56

Address

Hawthorn Lane 34 Heald Court 3
SK9 5DG Wilmslow

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

UNIVERSITE PARIS-SACLAY

France

EU contribution

€ 274 802,04

Address

Immeuble Technologique Entree B Rte De L Orme Aux Merisiers
91190 Saint Aubin

Activity type

Higher or Secondary Education Establishments

MILTENYI BIOTEC BV & CO KG

Germany

EU contribution

€ 252 788,40

Address

Friedrich Ebert Strasse 68
51429 Bergisch Gladbach

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

RESEARCH FUND OF THE HADASSAH MEDICAL ORGANIZATION (R.A)

Israel

EU contribution

€ 263 500,92

Address

Kiryat Hadassah Ein Karem
91120 Jerusalem

Activity type

Research Organisations